These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38319811)

  • 1. Should We "PROpel" Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?
    VanderWeele DJ; Hussain M
    NEJM Evid; 2022 Sep; 1(9):EVIDe2200154. PubMed ID: 38319811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
    Hussain M; Kocherginsky M; Agarwal N; Adra N; Zhang J; Paller CJ; Picus J; Reichert ZR; Szmulewitz RZ; Tagawa ST; Kuzel TM; Bazzi LA; Daignault-Newton S; Whang YE; Dreicer R; Stephenson RD; Rettig MB; Shevrin D; Gerke T; Chinnaiyan AM; Antonarakis ES
    Clin Cancer Res; 2024 Oct; 30(19):4318-4328. PubMed ID: 39115414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study.
    Xie J; Guo H; Dong B; Chen W; Jin C; Xu Q; Ding L; Liu W; Dong S; Zhao T; Yu Y; Guo C; Yao X; Peng B; Yang B
    Eur Urol Oncol; 2024 Oct; 7(5):1088-1096. PubMed ID: 38458891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
    Zhu Q; Chen J; Liu H; Zhao J; Xu C; Sun G; Zeng H
    BMC Cancer; 2024 Jun; 24(1):706. PubMed ID: 38851712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.
    McKay RR; Morgans AK; Shore ND; Dunshee C; Devgan G; Agarwal N
    Cancer Treat Rev; 2024 May; 126():102726. PubMed ID: 38613872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    de Bono J; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Mehra N; Goessl C; Kang J; Burgents J; Wu W; Kohlmann A; Adelman CA; Hussain M
    N Engl J Med; 2020 May; 382(22):2091-2102. PubMed ID: 32343890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    Clarke NW; Armstrong AJ; Thiery-Vuillemin A; Oya M; Shore N; Loredo E; Procopio G; de Menezes J; Girotto G; Arslan C; Mehra N; Parnis F; Brown E; Schlürmann F; Joung JY; Sugimoto M; Virizuela JA; Emmenegger U; Navratil J; Buchschacher GL; Poehlein C; Harrington EA; Desai C; Kang J; Saad F
    NEJM Evid; 2022 Sep; 1(9):EVIDoa2200043. PubMed ID: 38319800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib for the treatment of metastatic prostate cancer.
    Dror CM; Wyatt AW; Chi KN
    Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With
    Fallah J; Xu J; Weinstock C; Brave MH; Bloomquist E; Fiero MH; Schaefer T; Pathak A; Abukhdeir A; Bhatnagar V; Chiu HJ; Ricks T; John C; Hamed S; Lee C; Pierce WF; Kalavar S; Philip R; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman D
    J Clin Oncol; 2024 Feb; 42(5):605-613. PubMed ID: 38127780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
    Kwon DH; Booth CM; Prasad V
    Eur Urol; 2021 Jun; 79(6):710-712. PubMed ID: 33722420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
    VanderWeele DJ; Hussain M
    Clin Adv Hematol Oncol; 2020 Dec; 18(12):808-815. PubMed ID: 33406057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence.
    Yang J; Xiong X; Zheng W; Liao X; Xu H; Yang L; Wei Q
    Curr Oncol; 2023 Dec; 30(12):10311-10324. PubMed ID: 38132385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of Olaparib as a treatment option for metastatic castration-resistant prostate cancer.
    Mourmouris P; Papatsoris A; Dellis A; Mitsogiannis I; Chakra MA; Moussa M
    Expert Opin Pharmacother; 2021 Oct; 22(15):1955-1959. PubMed ID: 34252319
    [No Abstract]   [Full Text] [Related]  

  • 19. Research progress on the treatment of advanced prostate cancer with Olaparib.
    Su YX; Yu CF; Xue P; Li LL; Xiao KM; Chu XL; Zhu SJ
    Neoplasma; 2021 Nov; 68(6):1132-1138. PubMed ID: 34779643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
    Adashek JJ; Jain RK; Zhang J
    Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.